Neurobio Tech gets memantine milestone from Merz

2 May 2001

Neurobiological Technologies has received a second payment of $2.25million from Merz + Co for achieving goals relating to the neuroprotective agent memantine, currently in a Phase III trial for the treatment of Alzheimer's disease, neuropathic pain and AIDS-related dementia. The payment follows previous sums received by Merz under licensing deals between the company and Forest Laboratories and A/S Lundbeck for memantine (Marketletter August 21, 2000). Neurobiological says that this second payment indicates it is one step closer to the successful launch of memantine.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight